1 min read

ID: 745354

Short Link: https://gregory-ms.com/articles/745354/

Discovery Date: 22 July 2022, 17:55:05 UTC

Published Date: 2022-07-22 10:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/35866514/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220722135505&v=2.17.7

Manual Selection: true

Machine Learning Gaussian Naive Bayes Model: false

Abstract

Fingolimod (FTY720) is an oral drug approved by the Food and Drug Administration (FDA) for management of Multiple Sclerosis (MS) symptoms, which has also shownbeneficial effects against Alzheimer’s (AD) and Parkinson’s (PD) diseases pathologies. Although an extensive effort has been made to identify mechanisms underpinning its therapeutic effects, much remains unknown. Here, we investigated Fingolimod induced proteome changes in the cerebellum (CB) and frontal cortex (FC) regions of the brain…

Noun Phrases in Title

  • Fingolimod effects
  • the brain
  • biochemical modulation
  • bioenergetics
  • autophagy
  • neuroinflammatory networks
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.